Diabetes and Heart Disease & Stroke Prevent Programs-Improving the Health of Americans through Prevention and Management of Diabetes and Heart Disease and Stroke | CDC RFA DP18 1815

Opportunity Information: Apply for CDC RFA DP18 1815

The funding opportunity titled "Diabetes and Heart Disease and Stroke Prevent Programs - Improving the Health of Americans through Prevention and Management of Diabetes and Heart Disease and Stroke" (Funding Opportunity Number: CDC RFA DP18-1815) is a CDC cooperative agreement designed to help every state and the District of Columbia strengthen public health efforts that prevent and better manage two closely linked sets of conditions: diabetes (including prediabetes and type 2 diabetes risk) and cardiovascular disease (CVD), including heart disease and stroke risk factors. The overall purpose is to improve health outcomes by supporting state-level implementation and evaluation of evidence-based strategies, with a clear emphasis on reaching communities and populations carrying a disproportionate burden of disease.

A defining feature of this Notice of Funding Opportunity (NOFO) is that it is non-competitive and structured to support broad, statewide participation rather than selecting only a small number of winners. The CDC anticipated 51 awards, which aligns with awarding to all states plus the District of Columbia. The award ceiling is listed as $3,000,000, and the program is administered by the Department of Health and Human Services, Centers for Disease Control and Prevention, specifically within NCCDPHP (the National Center for Chronic Disease Prevention and Health Promotion). The CFDA number associated with this opportunity is 93.426, and the eligible applicants are state governments (with additional eligibility details referenced in the full announcement). Applications in the original cycle were due June 11, 2018, by 11:59 p.m. Eastern Time.

The NOFO centers on improving outcomes in "high-burden" populations and communities. In this context, high-burden does not just mean high prevalence of disease; it specifically refers to groups disproportionately affected by high blood pressure, high blood cholesterol, diabetes, or prediabetes because of socioeconomic or structural factors. Examples of the kinds of disparities the NOFO calls out include inadequate access to care, poor quality of care, and low income. In other words, states are expected to target their work where the need is greatest and where inequities in prevention, treatment, and ongoing management are most pronounced.

Program work is organized into two categories that must both be addressed. Category A focuses on diabetes management and the prevention of type 2 diabetes, which typically involves approaches that improve identification of prediabetes, connect people to proven lifestyle change or prevention programs, and strengthen systems of care and self-management supports for people already living with diabetes. Category B focuses on CVD prevention and management, which commonly includes strategies to improve detection and control of high blood pressure, reduce high cholesterol risk, and strengthen clinical and community supports that prevent heart attacks and strokes. Rather than prescribing a single approach, the NOFO provides a "menu of strategies" in each category, and applicants choose the strategies that best match their capacity, expertise, partnerships, and the areas where they can realistically achieve the largest reach and measurable impact.

A major theme of the opportunity is integration and reinforcement across diabetes and CVD work, reflecting how closely these conditions overlap in real-world populations and healthcare settings. Where it makes sense, states are encouraged to implement their chosen Category A and Category B strategies in the same targeted communities or settings so the interventions work together rather than competing for attention or resources. The NOFO explicitly notes that complementary strategies should be designed to benefit both groups: people with prediabetes or diabetes and people with high blood pressure and people with or at risk for high blood cholesterol. Practically, this points toward coordinated efforts in shared settings such as healthcare systems, community health centers, pharmacies, workplaces, or community-based organizations, where screening, referral, education, and ongoing support can address multiple risk factors at once.

Another key requirement is balance in how the work is resourced and staffed. The NOFO states that funding, resources, and level of effort should be divided equally between Category A and Category B strategies. This is meant to ensure states do not focus heavily on one disease area at the expense of the other, and it reinforces the program's intent to advance prevention and management of diabetes and cardiovascular risk factors as parallel priorities within a single coordinated award.

Finally, the opportunity emphasizes not only implementation but also evaluation of evidence-based strategies. That means states are expected to track progress, measure reach into priority populations, and assess whether the selected interventions are producing improvements such as better prevention uptake, stronger disease management, and ultimately improved health indicators in high-burden communities. The cooperative agreement structure also implies an ongoing partnership with CDC, where technical assistance, performance expectations, and reporting are typically more hands-on than in a standard grant, supporting consistent adoption of proven approaches across jurisdictions while still allowing states to tailor strategies to local needs.

• The Department of Health and Human Services, Centers for Disease Control - NCCDPHP in the health sector is offering a public funding opportunity titled "Diabetes and Heart Disease & Stroke Prevent Programs-Improving the Health of Americans through Prevention and Management of Diabetes and Heart Disease and Stroke" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.426.
• This funding opportunity was created on May 18, 2018.
• Applicants must submit their applications by Jun 11, 2018 Electronically submitted applications must be submitted no later than 1159 p.m., ET, on the listed application due date.. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• Each selected applicant is eligible to receive up to $3,000,000.00 in funding.
• The number of recipients for this funding is limited to 51 candidate(s).
• Eligible applicants include: State governments, Others (see text field entitled Additional Information on Eligibility for clarification).

Apply for CDC RFA DP18 1815

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: